一项针对复发性前列腺癌的18F-PSMA PET/CT前瞻性省级注册研究:4,135例男性结果
PREP研究在加拿大安大略省纳入4,135例根治性治疗(前列腺切除术或放疗)后疑似复发的前列腺癌男性,于2018年10月至2022年9月期间在6个参与中心接受18F-DCFPyL PET/CT。中位随访1.8年,PET/CT阳性率较高,PET/CT后疾病管理改变是总生存改善的独立预测因素。
要点
- PREP注册研究纳入4,135例复发性前列腺癌男性,接受18F-DCFPyL PET/CT。
- PET/CT阳性显著预测因素包括PET/CT时较高PSA水平和临床队列。
- PET/CT后疾病管理改变是总生存改善的独立预测因素。
核心结论
- PREP研究促进了18F-PSMA PET/CT的可及性并显示高疾病检出率。
- 与生存显著相关的因素为临床情景、转移模式和18F-PSMA PET/CT后疾病管理改变。
研究设计与样本
- 研究为在加拿大安大略省开展的前瞻性省级注册研究(PSMA-PET Registry for Recurrent Prostate Cancer,PREP)。
- 2018年10月至2022年9月共纳入4,135例男性,入组条件为既往根治性治疗(根治性前列腺切除术或放疗)后疑似前列腺癌复发。
- 受试者纳入6个预设临床队列之一,并在6个参与中心之一接受18F-DCFPyL PET/CT。
- 标准化报告描述复发部位及PET/CT后疾病管理改变,并与省级数据库链接以估算总生存和PET/CT后挽救性放疗的使用。
主要发现
- 中位随访1.8年。
- 多因素分析中PET/CT阳性的显著预测因素包括PET/CT时较高的前列腺特异性抗原水平和队列(以队列4最高,该队列癌症在挽救性激素治疗期间进展)。
- 管理改变的显著预测因素为复发类型(以孤立性局部区域病变最高)和较高前列腺特异性抗原水平。
- 总生存较差的显著预测因素包括队列(以队列4最差)和转移的范围与类型(以混合骨、淋巴结和内脏转移或广泛转移最差)。
- PET/CT后疾病管理改变是总生存率改善的显著独立预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The PSMA-PET Registry for Recurrent Prostate Cancer study was initiated in Ontario, Canada, to provide access to and characterize the performance of 18F-prostate-specific membrane antigen (PSMA) PET/CT among men with recurrent prostate cancer. Methods: Between October 2018 and September 2022, 4,135 men were enrolled in PREP. Eligibility included suspected prostate cancer recurrence after prior definitive treatment (radical prostatectomy or radiotherapy). Men were enrolled in 1 of 6 predefined clinical cohorts and imaged with 18F-DCFPyL at 1 of 6 participating sites. Standardized reports delineated sites of recurrence and changes in disease management after PET/CT. Linkage to provincial databases allowed estimation of overall survival (OS) and use of salvage radiotherapy after PET/CT. Results: The median follow-up was 1.8 y. Significant predictors of a positive PET/CT scan on multivariate analysis included a higher prostate-specific antigen level at the time of PET/CT and cohort (highest for cohort 4, whose cancer had progressed during salvage hormone therapy). Significant predictors of management change were type of recurrence (highest for isolated locoregional disease) and higher prostate-specific antigen level. Significant predictors of worse OS included cohort (worst for cohort 4) and extent and type of metastases (worst for mixed bone, lymph, and visceral or extensive metastases). A change in disease management after PET/CT was a significant independent predictor of improved OS rates. Conclusion: PREP facilitated access to 18F-PSMA PET/CT and demonstrated high rates of disease detection. Significant factors associated with survival were clinical scenario, pattern of metastases, and change in disease management after 18F-PSMA PET/CT.
引用
- Kohan A, Metser U, Luke W, et al. A Prospective Provincial Registry of 18F-PSMA PET/CT for Recurrent Prostate Cancer: Results for 4,135 Men. J Nucl Med. 2025. PMID: 40610233. doi:10.2967/jnumed.125.269653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。